Download
lighting the way with xelox xeloda plus oxaliplatin n.
Skip this Video
Loading SlideShow in 5 Seconds..
Lighting the way with XELOX (Xeloda plus oxaliplatin) PowerPoint Presentation
Download Presentation
Lighting the way with XELOX (Xeloda plus oxaliplatin)

Lighting the way with XELOX (Xeloda plus oxaliplatin)

262 Views Download Presentation
Download Presentation

Lighting the way with XELOX (Xeloda plus oxaliplatin)

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Lighting the way with XELOX (Xeloda plus oxaliplatin) Josep Tabernero Vall d’Hebron University HospitalBarcelona, Spain

  2. Xeloda + 3-weekly oxaliplatin: rigorous preclinical and clinical development program Preclinical:evidence of synergy1 Phase I:recommended regimen identified2 Phase II:highly effective and well tolerated first-line treatment for metastatic colorectal cancer (MCRC)1 Phase III: adjuvant and metastatic settings 1Cassidy J et al. J Clin Oncol 2004;22:2084–91 2Díaz-Rubio E et al. Ann Oncol 2002;13:558–65

  3. Supra-additive activity of XELOX in human colon cancer CXF280 xenografts Tumor volume (cm3) 10 5 1 0.5 0.1 Control Xeloda (2/3 MTD) Oxaliplatin (2/3 MTD) Combination (both 2/3 MTD) 1 11 21 31 41 51 Days after drug treatment *p<0.05 vs both single agentsMTD = maximum tolerated dose Cassidy J et al. J Clin Oncol 2004;22:2084–91

  4. 1 8 15 21 Day Oxaliplatin130mg/m2 (2-hour infusion) Xeloda1000mg/m2 twice daily Day 1 (pm)–15 (am) Rest Repeat cycle at day 22 XELOX international phase II trial:first-line in MCRC (n=96) Regimen recommended from phase I trial1 • Male/female (%) = 64 / 36; median age = 64 years2 • 28% prior (neo)adjuvant therapy 1Díaz-Rubio E et al. Ann Oncol 2002;13:558–65 2Cassidy J et al. J Clin Oncol 2004;22:2084–91

  5. First-line XELOX produces consistently high response rates across subgroups Patients (%) 80 60 40 20 0 61 60 60 56 55 55 55 54 53 50 Overall Liver Lung Yes No £80 >80 <60 ³60 Metastases (Neo)adjuvant KPS Age chemotherapy KPS = Karnofsky performance status Cassidy J et al. J Clin Oncol 2004;22:2084–91

  6. XELOX: median progression-freesurvival (PFS) of 7.7 months (n=96) Estimated probability 1.0 0.8 0.6 0.4 0.2 0.0 Median: 7.7 months(95% CI: 6.4–8.6) 0 2 4 6 8 10 12 14 16 18 20 22 Months Cassidy J et al. J Clin Oncol 2004;22:2084–91

  7. XELOX: median overall survival of 19.5 months (n=96) Estimated probability 1.0 0.8 0.6 0.4 0.2 0.0 19.5 months (95% CI: 15.3–21.6) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 Months Cassidy J et al. J Clin Oncol 2004;22:2084–91

  8. XELOX: favorable safetyprofile compared with FOLFOX4 1Cassidy J et al. J Clin Oncol 2004;22:2084–912Goldberg R et al. J Clin Oncol 2004;22:23–303de Gramont A et al. J Clin Oncol 2000;18:2938–47

  9. Medical cost savings associated with XELOX versus FOLFOX Net costs per patient versus FOLFOX ($) 4000 2000 0 –2000 –4000 –6000 –2043 –2571 –4614 Total Savings Drug and Treatment of administration adverse events Chu E et al. Proc Am Soc Clin Oncol 2003;22:269 (Abst 1080)

  10. Large phase II–III trial program of Xeloda + oxaliplatin in MCRC ORR = overall response rateTTP = time to progression

  11. Ongoing phase III trial: XELOX ± Avastin versus FOLFOX4 ± Avastin (XELOX1*) • 2x2 factorial, randomized phase III trial Avastin 5mg/kg every 2 weeks (n=330) PD FOLFOX4 (n=300) Previously untreated patients with MCRC(n=1920) Placebo (n=330) PD Avastin 7.5mg/kg every 3 weeks (n=330) PD XELOX (n=300) Placebo (n=330) PD • Primary objectives • at least equivalent TTP with XELOX (± Avastin) versus FOLFOX4 (± Avastin) • superior TTP with Avastin + XELOX/FOLFOX versus XELOX/FOLFOX PD = disease progression *Roche registration study

  12. Randomized TREE study comparing Xeloda and 5-FU/LV + oxaliplatin (n=223) (n=150) TREE1 TREE2: + Avastin (B) RAN D O M I Z A T I O N FOLFOX(infusional 5-FU/LV + oxaliplatin) FOLFOX-B bFOL(bolus 5-FU/LV + oxaliplatin) Stage IV disease First line bFOL-B XELOX XELOX-B • Equivalent safety profile • Equivalent activity • Avastin significantly improved ORR Hoechster HS et al. Proc ASCO GI 2005 (Abst 241)

  13. First-line XELOX versus infused 5-FU + oxaliplatin: Spanish phase III trial • 1º objective • TTP XELOX Xeloda 1000mg/m2 day 1 (pm)–15 (am) Oxaliplatin 130mg/m2, day 1 First-line MCRCn=348 5-FU (TTD) + oxaliplatin 48-hour 5-FU 2250mg/m2, weekly + oxaliplatin 85mg/m2, every 2 weeks Aranda E et al. Ann Oncol 2004;15(Suppl. 3):iii82 (Abst 307P)

  14. Favorable safety of XELOX in Spanish phase III trial: grade 3 / 4 adverse events (n=286) Patients (%) XELOX 48-hour 5-FU (TTD) days 1 and 8 + oxaliplatin 85mg/m2day 14, q14d 40 30 20 10 0 Nausea Anemia Diarrhea Asthenia Vomiting Anorexia Neutropenia Paresthesiae Aranda E et al. Ann Oncol 2004;15(Suppl. 3):iii82 (Abst 307P)

  15. Trials investigating other regimens combining Xeloda with oxaliplatin

  16. Standard XELOX versus dose intense Xeloda/oxaliplatin: randomized phase II • 1º objective • PFS • No prospective efficacy comparison Standard XELOX Xeloda 1000mg/m2 days 1–14 Oxaliplatin 130mg/m2, day 1, every 21 days First-line MCRCn=89 Dose-intense (DI) Xeloda + oxaliplatin Xeloda 1750mg/m2 days 1–7, 14–21 Oxaliplatin 85mg/m2, days 1, 14 every 28 days Scheithauer W et al. J Clin Oncol 2003;21:1307–12

  17. First-line CAPOX versus infused FUFOX:German phase III trial • 1º objective • PFS CAPOX Xeloda 1000mg/m2 days 1 (pm)–15 (am) Oxaliplatin 70mg/m2, days 1, 8 1st-line MCRCn=476 FUFOXOxaliplatin 50mg/m2 + LV 500mg/m25-FU 2000mg/m2 (24-hour), days 1, 8, 15, 22 every 6 weeks

  18. Favorable safety of CAPOX versus FUFOX: treatment-related grade 3/4 adverse events Patients (%) 40 30 20 10 0 CAPOX FUFOX Pain Nausea Diarrhea Infection Vomiting Hand-foot syndrome Stomatitis Neuropathy Arkenau HT et al. Proc 2005 GI Cancers Symposium 2005;197 (Abst 226)

  19. XELOX: favorable safety profile compared with 5-FU-based combinations • Safety profile of Xeloda + oxaliplatin compares favourably with 5-FU/LV + oxaliplatin • in cross-trial1–3 and direct comparison4,5 • Xeloda-based versus 5-FU/LV-based regimens associated with • similar incidence of diarrhea, nausea/vomiting, sensory neuropathy • higher incidence of hand-foot syndrome • particularly low incidence of neutropenia compared with 5-FU/LV-based regimens 1Cassidy J et al. J Clin Oncol 2004;22:2084–91; 2Goldberg R et al. J Clin Oncol 2004;22:23–30 3de Gramont A et al. J Clin Oncol 2000;18:2938–47; 4Aranda E et al. Ann Oncol 2004;15(Suppl. 3):iii82 (Abst 307P) 5Arkenau HT et al. Proc 2005 GI Cancers Symposium 2005;197 (Abst 226)

  20. XELOX: favorable safety profile compared with 5-FU-based combinations 1Cassidy J et al. J Clin Oncol 2004;22:2084–91; 2Goldberg R et al. J Clin Oncol 2004;22:1–8 3de Gramont A et al. J Clin Oncol 2000;18:2938–47; 4Aranda E et al. Ann Oncol 2004;15(Suppl. 3):iii82 (Abst 307P) 5Arkenau HT et al. Proc 2005 GI Cancers Symposium 2005;197 (Abst 226)

  21. Favorable response rates with Xeloda/oxaliplatin versus 5-FU/LV/oxaliplatin Response (%) 60 50 40 30 20 10 0 XELOX (n=96)1 XELOX (n=45)2 DI XELOX (n=44)2 FOLFOX (n=267)3 FOLFOX (n=210)4 XELOX (n=39)5 FOLFOX (n=45)5 CAPOX (n=142)6 FUFOX (n=133)6 1Cassidy J et al. J Clin Oncol 2004;22:2084–91; 2Scheithauer W et al. J Clin Oncol 2003;21:1307–12 3Goldberg R et al. J Clin Oncol 2004;22:23–30; 4de Gramont A et al. J Clin Oncol 2000;18:2938–47 5Hochster HS et al. Proc 2005 GI Cancers Symposium 2005;204 (Abst 241) 6Arkenau HT et al. Proc 2005 GI Cancers Symposium 2005;197 (Abst 226)

  22. Xeloda is an effective, well tolerated combination partner for oxaliplatin • Xeloda plus oxaliplatin is at least as effective and well tolerated compared with 5-FU/LV plus oxaliplatin • Xeloda plus oxaliplatin is a convenient schedule because it avoids the use of central venous devices and pumps • Ongoing phase III trials have been designed to establish that Xeloda is the combination partner of choice for oxaliplatin • Combination of XELOX with biological agents should further improve outcomes